Innovative drug update | Kexing Biopharm enrolls the first subject in the Phase I clinical trial in China for the innovative ophthalmic drug GB10

▤ Summary

Kexing Biopharm announced that the first patient has been dosed in the Phase I clinical trial in China for GB10, an innovative ophthalmic injection. The drug targets neovascular age-related macular degeneration and uses a bispecific antibody approach against VEGF and Ang-2. The company says the asset could support longer dosing intervals and better patient adherence, and preclinical data suggest strong biological activity and in vivo efficacy. Kexing also says it is expanding its ophthalmic R&D pipeline and pursuing international growth with both in-house and externally sourced products.

▦ Linked Companies